GLA antibody

Catalog No. ABIN7114447

This Rabbit Polyclonal antibody specifically detects GLA in WB, IHC, ELISA and IP. It exhibits reactivity toward Human, Mouse and Rat.

Quick Overview for GLA antibody (ABIN7114447)

Target: GLA (Galactosidase, alpha (GLA))

Reactivity: Human, Mouse, Rat

Host: Rabbit

Clonality: Polyclonal

Conjugate: This GLA antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC), ELISA, Immunoprecipitation (IP)

Product Details anti-GLA Antibody

Purification: Immunogen affinity purified

Purity: ≥95 % as determined by SDS-PAGE

Immunogen: galactosidase, alpha

Isotype: IgG

Application Details

Application Notes: WB: 1:500-1:5000, IHC: 1:20-1:200, IP: 1:500-1:5000

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: PBS with 0.02 % sodium azide and 50 % glycerol pH 7.3,

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: -20°C for 12 months (Avoid repeated freeze / thaw cycles.)

Expiry Date: 12 months

Target Details for GLA

Target: GLA (Galactosidase, alpha (GLA))

Alternative Name: Alpha galactosidase A

Background: Synonyms:Alpha galactosidase A, galactosidase, alpha Background:GLA, also named as Melibiase, Agalsidas and Alpha-galactosidase A, Belongs to the glycosyl hydrolase 27 family. It hydrolysis of terminal, non-reducing alpha-D-galactose residues in alpha-D-galactosides, including galactose oligosaccharides, galactomannans and galactolipids. Fabry disease is an X-linked lysosomal storage disorder resulting from the deficient activity of GLA. Enzyme replacement therapy(ERT) with GLA is currently the most effective therapeutic strategy for patients with Fabry disease, a lysosomal storage disease.

Molecular Weight: 49 kDa

Gene ID: 2717

UniProt: P06280

Pathways: SARS-CoV-2 Protein Interactome